Date: 2015-08-27
Type of information: Company acquisition
Acquired company: MB2 (USA - IN)
Acquiring company: Novo Nordisk (Denmark)
Amount: undisclosed
Terms: * On August 27, 2015, Novo Nordisk announced that it has entered into a definitive agreement under which Novo Nordisk will acquire MB2 LLC, a privately held biopharmaceutical research company based in Indiana, US. The acquisition will expand Novo Nordisk's portfolio of projects and intellectual property rights within diabetes and obesity and provide a basis for expanding Novo Nordisk's research presence in the US. The parties have agreed not to disclose the financial details of the transactions. The closing of the transaction is subject to US regulatory approval and is expected to occur during the third quarter of 2015.
Details: Formed in 2014, MB2 is a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class, mixed agonist drugs for the treatment of diabetes and obesity. MB2 was co-founded by Kent Hawryluk, chief executive officer and Richard DiMarchi, PhD, chief scientific officer.
Related: Diabetes Metabolic diseasees
